Aptose Biosciences Appoints New Independent Auditor

The latest announcement is out from Aptose Biosciences ( (TSE:APS) ).

On August 22, 2025, Aptose Biosciences announced the appointment of Ernst & Young LLP as their new independent auditor, highlighting the firm’s expertise in the life sciences sector. Additionally, Aptose received a US$1.5 million advance from Hanmi Pharmaceutical to further develop their tuspetinib-based therapy for AML, as part of an existing loan agreement.

The most recent analyst rating on (TSE:APS) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.

Spark’s Take on TSE:APS Stock

According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.

Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.

To see Spark’s full report on TSE:APS stock, click here.

More about Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for unmet medical needs in oncology, particularly in hematology. Their lead product, tuspetinib, is an oral kinase inhibitor being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML).

Average Trading Volume: 7,047

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$4.42M

Find detailed analytics on APS stock on TipRanks’ Stock Analysis page.